Next 10 |
home / stock / asclf / asclf news
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...
2024-01-28 09:05:00 ET Summary ArriVent BioPharma (NSDQ: AVBP), a Philadelphia in-licensing company, priced its upsized NASDAQ IPO at $18 per share, raising $175 million. A siRNA therapy developed by Shanghai Refreshgene Therapeutics enables children with genetic deafness to hear....
2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...
Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...
Ascletis Pharma ( OTCPK:ASCLF ) subsidiary Ascletis Pharmaceuticals enters a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical, a subsidiary of Simcere Pharmaceutical Group. Ascletis currently owns the only authorized ritonavir oral tablet in China, wh...
Summary Chengdu WestGene Biopharma completed a $21 million Series A Round to advance its portfolio of nearly 20 mRNA candidates, including its lead COVID-19 vaccine, which is in IND stage. Suzhou GenAssist Therapeutics raised “millions of dollars” in an A round to support ...
Ascletis Pharma ( OTCPK:ASCLF ) said China's National Medical Products Administration (NMPA) approved its investigational new drug (IND) application to start a trial of oral drug ASC11 for COVID-19. The goal of the phase 1 trial, which is expected to be completed within Q1 2023, ...
News, Short Squeeze, Breakout and More Instantly...
Ascletis Pharma Inc. Company Name:
ASCLF Stock Symbol:
OTCMKTS Market:
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...